JAK inhibitor Ruxolitinib, Purity ≥98%

Cat. No.: X23-10-ZQ381

JAK inhibitor Ruxolitinib, Purity ≥98%

Synonym: Ruxolitinib; 941678-49-5; INCB018424; Ruxolitinib (INCB018424); (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile; JAK inhibitor

  • MDL: MFCD12031592
  • CAS Number: 941678-49-5
  • Compound CID: 25126798
Product Size
5 mg; 10 mg; 25 mg; 50 mg; 100 mg
Price
Datasheet
MSDS
Properties
Description
Ruxolitinib, soluble in DMSO and ethanol and insoluble in water, is an available JAK small molecule inhibitor with potential antineoplastic activity. It targets JAK1, JAK2, JAK3, and Tyk2.
Molecular Weight
306.4
Molecular Formula
C17H18N6
Targets
JAK1: 3.3 nM; JAK2: 2.8 nM; JAK3: 428 nM; Tyk2: 19 nM
Form
Lyophilized powder
Purity
≥98%
Solubility
DMSO: 59 mg/mL (192.57 mM); Water: Insoluble; Ethanol: 59 mg/mL (192.57 mM)
Identity
Confirmed by NMR/HPLC/MS.
Stability
The product is stable for three years when stored at the recommended temperature in lyophilized powder.
Applications
Ruxolitinib can be applied to research associated with the inhibition of JAK1 and JAK2 signaling.
Storage
Store at -20ºC.
Related Products

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.